16
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Modulation of sphingosine 1-phosphate (S1P) receptors in a non-selective manner decreases disease activity in patients with multiple sclerosis but has potential safety concerns. We assessed the safety and efficacy of the oral selective S1P receptor modulator ozanimod in patients with relapsing multiple sclerosis.

          Related collections

          Author and article information

          Journal
          Lancet Neurol
          The Lancet. Neurology
          Elsevier BV
          1474-4465
          1474-4422
          Apr 2016
          : 15
          : 4
          Affiliations
          [1 ] Mellen Center for MS Treatment and Research, Cleveland Clinic, Cleveland, OH, USA. Electronic address: cohenj@ccf.org.
          [2 ] NeuroRx Research and Montreal Neurological Institute, Department of Neurology and Neurosurgery, McGill University, Montreal, QC, Canada.
          [3 ] San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Neurology, Milan, Italy.
          [4 ] Montreal Neurological Institute, Department of Neurology and Neurosurgery, McGill University, Montreal, QC, Canada.
          [5 ] Receptos Inc, Clinical Development, San Diego, CA, USA.
          [6 ] Neurology Center, Lodz, Poland.
          Article
          S1474-4422(16)00018-1
          10.1016/S1474-4422(16)00018-1
          26879276

          Comments

          Comment on this article